Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Protagonist Therapeutics (PTGX) will participate in two investment bank conferences in New York in September 2026, featuring fireside chats with President and CEO Dinesh V. Patel, Ph.D.
Protagonist Therapeutics (PTGX) will participate in two investment bank conferences in New York in September 2026, featuring fireside chats with President and CEO Dinesh V. Patel, Ph.D.
The company presents at the Citi Biopharma Back to School Conference on September 9, 2026 at 10:40 A.M. ET and at the 2026 Cantor Global Healthcare Conference on September 10, 2026 at 10:20 A.M. ET, with webcasts and one-year replays available via its Investor Relations webpage.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
PTGX gained 2.37% after the August 28 FDA approval announcement. Against that history, this conferen...
Analysis
PTGX gained 2.37% after the August 28 FDA approval announcement. Against that history, this conference schedule offered no reported operating, clinical, or regulatory result; recent insider activity was net selling, a relevant risk context.
Key Figures
Investment bank conferences:2 conferencesCiti conference dates:September 9-10, 2026Citi fireside chat:10:40 A.M. ET+5 more
8 metrics
Investment bank conferences2 conferencesSeptember 2026
Citi conference datesSeptember 9-10, 2026Citi Biopharma Back to School Conference
Citi fireside chat10:40 A.M. ETWednesday, September 9, 2026
Cantor conference datesSeptember 9-11, 20262026 Cantor Global Healthcare Conference
Cantor fireside chat10:20 A.M. ETThursday, September 10, 2026
Replay availability1 yearInvestor Relations Events and Presentations webpage
The company granted equity awards to three recently hired employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The two recent positive corporate announcements were followed by gains, while inducement-award reactions diverged.
Key Terms
fda-approved, interleukin-23 receptor, phase 3, hepcidin mimetic peptide, +1 more
5 terms
fda-approvedregulatory
"has now produced two FDA-approved, first-in-class medicines"
FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.
interleukin-23 receptormedical
"precisely blocks the Interleukin-23 receptor"
A protein on the surface of certain immune cells that binds the signaling molecule interleukin-23 (IL-23) to trigger inflammatory responses. It acts like a lock that only the IL-23 key fits, turning on pathways that help defend against infection but can also drive chronic inflammation in conditions such as psoriasis and inflammatory bowel disease. Investors watch it because medicines that block this receptor can reduce disease activity, making it a common target in drug development and licensing deals.
phase 3medical
"is in Phase 3 development for psoriatic arthritis"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
hepcidin mimetic peptidemedical
"a first-in-class hepcidin mimetic peptide licensed to Takeda"
A hepcidin mimetic peptide is a short chain of amino acids engineered to act like hepcidin, the body’s natural hormone that controls iron levels by telling cells to hold on to iron and reducing iron release into the bloodstream. Investors care because these experimental drugs aim to treat iron-overload or chronic anemia conditions by changing how the body handles iron, and their progress through trials, approvals, and manufacturing can affect a biotech company’s value.
erythrocytosismedical
"approved in the U.S. for the treatment of erythrocytosis"
Erythrocytosis is an increase in the number or concentration of red blood cells in the bloodstream, which makes blood thicker—similar to syrup becoming more viscous than water. For investors, it matters because it can be a side effect or safety signal in drug development, a reason for regulatory scrutiny, or a factor that affects clinical trial outcomes and potential market approval, liability, or sales for healthcare companies.
NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in September 2026.
Citi Biopharma Back to School Conference; New York, NY - September 9-10, 2026
Format: Fireside Chat Day/Time: Wednesday, September 9 at 10:40 A.M. ET Webcast: HERE
2026 Cantor Global Healthcare Conference; New York, NY - September 9-11, 2026
Format: Fireside Chat Day/Time: Thursday, September 10 at 10:20 A.M. ET Webcast: HERE
If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.
Protagonist Therapeutics is a biopharmaceutical company built on a proprietary peptide technology platform that has now produced two FDA-approved, first-in-class medicines, generating royalties and milestones from global commercial partnerships with Johnson and Johnson and Takeda Pharmaceutical Company Limited. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026 for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further clinical and regulatory development and commercialization. Protagonist also discovered and led research and development through Phase 3 for MIMRYLO™ (rusfertide), a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceutical Company Limited for worldwide commercialization. MIMRYLO is approved in the U.S. for the treatment of erythrocytosis in adults with PV. The Company also has a number of clinical and preclinical programs based on clinically and commercially validated targets and addressing unmet medical needs, including an oral IL-17 antagonist peptide, anti-obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin discovery programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
When will Protagonist Therapeutics (PTGX) present at the Citi Biopharma Back to School Conference in September 2026?
Protagonist Therapeutics will participate in a fireside chat at the Citi Biopharma Back to School Conference in New York on Wednesday, September 9, 2026 at 10:40 A.M. ET. The session will be available via webcast.
What is the schedule for Protagonist Therapeutics (PTGX) at the 2026 Cantor Global Healthcare Conference?
Protagonist Therapeutics is scheduled for a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on Thursday, September 10, 2026 at 10:20 A.M. ET. The company will provide a webcast of this presentation.
How can investors access the Protagonist Therapeutics (PTGX) conference webcasts and replays?
Webcasts for both September 2026 fireside chats will be accessible online, and a replay of the presentations will be available on Protagonist Therapeutics' Investor Relations Events and Presentations webpage for one year following the events.
Can investors arrange one-on-one meetings with Protagonist Therapeutics (PTGX) during the September 2026 conferences?
Investors interested in meeting with the Protagonist Therapeutics team during the September 2026 Citi and Cantor conferences are asked to contact their respective conference representative to request or schedule meetings.
Which Protagonist Therapeutics (PTGX) executive is presenting at the September 2026 investment bank conferences?
Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics, will participate in fireside chats at both the Citi Biopharma Back to School Conference and the 2026 Cantor Global Healthcare Conference in New York.
What drugs has Protagonist Therapeutics (PTGX) developed that are already approved?
Protagonist Therapeutics' peptide platform has produced two FDA-approved, first-in-class medicines: ICOTYDE (icotrokinra), licensed to Janssen Biotech for plaque psoriasis and in Phase 3 for other indications, and MIMRYLO (rusfertide), licensed to Takeda for erythrocytosis in adults with PV.
What pipeline programs does Protagonist Therapeutics (PTGX) highlight in connection with its September 2026 conferences?
The company highlights clinical and preclinical programs targeting unmet medical needs, including an oral IL-17 antagonist peptide, anti-obesity dual and triple agonists, an oral hepcidin functional mimetic, and recently announced IL-4 and amylin discovery programs.
